Open Essex

The core challenge in cancer therapy is the precise elimination of malignant cells with minimal damage to healthy tissue. Antibody-based therapeutics offer a powerful solution, leveraging their exceptional specificity to target tumor-associated antigens. This approach has evolved from early antibodies that directly blocked cellular pathways to sophisticated systems like antibody-drug conjugates (ADCs) and immunocytokines, which deliver potent payloads directly to the disease site. Our services are designed to address this challenge by providing innovative solutions grounded in published scientific literature and proven preclinical models, enabling the development of highly effective targeted therapies.

Ligand-mediated Targeting-based Antibody Production
This strategy focuses on generating antibodies that target specific molecules or ligands that are overexpressed on cancer cells or within the tumor microenvironment. Examples include targeting growth factors and their receptors, such as the epidermal growth factor receptor or the vascular endothelial growth factor receptor, which are often critical for tumor growth and survival. By blocking these key signaling pathways, these antibodies can directly inhibit cancer cell proliferation and survival.

Cellular Targeting-based Antibody Production
This approach goes beyond just targeting cancer cells and focuses on engineering antibodies that can engage with specific cell types within the tumor microenvironment (TME). We specialize in developing bispecific antibodies that can simultaneously bind to a tumor cell and an immune effector cell, such as a T-cell or an NK cell. This effectively redirects the immune system to the tumor, leading to a potent and highly localized anti-cancer response, even in immune-suppressive TMEs.

Tissue-Specific Targeting-based Antibody Production
This service is designed to create antibodies that bind to antigens or biomarkers uniquely expressed in a specific tissue or organ, often related to the tumor's extracellular matrix (ECM) or vasculature. A prime example is a specific antibody that targets the extra domain B of fibronectin. This particular antigen is highly expressed in the ECM of a wide variety of solid tumors but is largely absent in normal healthy tissues, making it an ideal candidate for targeted delivery of a payload.

pH/Enzyme-Responsive Targeting-based Antibody Production
This innovative strategy involves designing antibody-payload conjugates with a built-in "release switch" that is activated by the unique conditions of the tumor microenvironment. The system remains stable and inactive in the systemic circulation, preventing off-target toxicity. The payload is released only when the antibody encounters the low pH or high concentrations of specific enzymes, which are characteristic of the tumor milieu. This ensures precision delivery and maximizes therapeutic efficacy at the disease site.